主要文件

查看所有文档

Y0000808

苯基丁酸钠

Name: 苯基丁酸钠
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

4-PBA, 4-苯丁酸钠, 4-苯基丁酸, 4-苯基丁酸钠, 三酷酸酯, 苯丁酸钠制剂

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₀H₁₁NaO₂

化学文摘社编号:

1716-12-7

分子量:

186.18

NACRES:

NA.24

PubChem Substance ID:

329831161

UNSPSC Code:

41116107

MDL number:

MFCD00800247

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

sodium phenylbutyrate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1

InChI key

VPZRWNZGLKXFOE-UHFFFAOYSA-M

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

苯基丁酸钠是一种组蛋白去乙酰化酶抑制剂。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 苯基丁酸钠

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2.

Sotaro Naoi et al.

The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)

To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile

No amelioration of uromodulin maturation and trafficking defect by sodium 4-phenylbutyrate in vivo: studies in mouse models of uromodulin-associated kidney disease.

Elisabeth Kemter et al.

The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)

Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive

Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension.

Masayuki Koyama et al.

American journal of physiology. Heart and circulatory physiology, 306(9), H1314-H1323 (2014-03-13)

Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and vascular remodeling of the pulmonary artery (PA). Recently, endoplasmic reticulum (ER) stress and inappropriate adaptation through the unfolded protein response (UPR) have been disclosed in various types of diseases. Here we

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000808	04061833805084